Ambrisentan vs F230

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: Endothelin A receptor · full Pulmonary Arterial Hypertension pipeline

Ambrisentan · Letairis

Marketed by Gilead Sciences and partners

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00423202 · Phase 3 · completed

The trial's own title and endpoint description confirm a randomized, double-blind, placebo-controlled design with a validated functional endpoint for pulmonary hypertension. Both doses significantly improved six-minute walk distance over placebo (+32 m at 2.5 mg, p=0.022; +59 m at 5 mg, p<0.001).

Next expected readout: February 2028 · NCT06987097 (registry estimate)

Reported efficacy

Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV (From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)): Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction (met)

Result source: NCT01178073

F230

Developed by Gyre Therapeutics and partners

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Pulmonary Arterial Hypertension

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

F230: no structured comparison results are available for Pulmonary Arterial Hypertension.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ambrisentan

Clinical Failure 18.2% (n=253) vs 28.1% (n=121) Tadalafil @ 87wk
event rate · % of participants
First adjudicated clinical failure event
NCT01178073 · Phase 3 · combination · converted to % from 46 Participants as posted
show 1 more result
34.1% (n=126) vs 28.1% (n=121) Tadalafil @ 87wk*
First adjudicated clinical failure event
NCT01178073 · Phase 3 · monotherapy · converted to % from 43 Participants as posted
All-cause Mortality 3.6% (n=253) vs 5% (n=121) Tadalafil @ 87wk
absolute value · percentage points
Death (all-cause)
NCT01178073 · Phase 3 · combination · converted to % from 9 Participants as posted
show 1 more result
1.6% (n=126) vs 5% (n=121) Tadalafil @ 87wk*
Death (all-cause)
NCT01178073 · Phase 3 · monotherapy · converted to % from 2 Participants as posted
Disease Progression Event 4% (n=253) vs 3.3% (n=121) Tadalafil @ 87wk
event count · % of participants
Disease progression
NCT01178073 · Phase 3 · combination · converted to % from 10 Participants as posted
show 1 more result
9.5% (n=126) vs 3.3% (n=121) Tadalafil @ 87wk*
Disease progression
NCT01178073 · Phase 3 · monotherapy · converted to % from 12 Participants as posted
NT-Pro BNP -67.15% (n=204) vs -43.83% (n=100) Tadalafil @ 24wk
percent change · % of baseline
NCT01178073 · Phase 3 · combination
show 1 more result
-56.15% (n=99) vs -43.83% (n=100) Tadalafil @ 24wk
NCT01178073 · Phase 3 · monotherapy
Satisfactory Clinical 39% (n=234) vs 27% (n=113) Tadalafil @ 24wk
responder rate · % of participants
NCT01178073 · Phase 3 · combination
show 1 more result
31% (n=113) vs 27% (n=113) Tadalafil @ 24wk
NCT01178073 · Phase 3 · monotherapy
6MWD - Change 48.98 vs 22.7 Tadalafil m @ 24wk
absolute change · m
NCT01178073 · Phase 3 · combination
show 7 more results
27 vs 22.7 Tadalafil m @ 24wk
NCT01178073 · Phase 3 · monotherapy
376.5 vs 442 placebo m @ 4wk
NCT00617305 · Phase 4 · registry result, not featured evidence
377.9 vs 422 placebo m @ 12wk
NCT00617305 · Phase 4 · registry result, not featured evidence
382.4 vs 422 placebo m @ 24wk
NCT00617305 · Phase 4 · registry result, not featured evidence
366.5 vs 402 placebo m @ 36wk
NCT00617305 · Phase 4 · registry result, not featured evidence
378.9 vs 402 placebo m @ 48wk
NCT00617305 · Phase 4 · registry result, not featured evidence
21.53 vs -16.53 placebo m @ 24wk
NCT02290613 · Phase 2 · registry result, not featured evidence
WHO Functional Class 0 vs 0 Tadalafil score @ 24wk
absolute change · score
NCT01178073 · Phase 3 · combination
show 1 more result
0 vs 0 Tadalafil score @ 24wk
NCT01178073 · Phase 3 · monotherapy
Borg Dyspnea -1 vs -0.5 Tadalafil score @ 24wk
absolute change · score
NCT01178073 · Phase 3 · combination
show 2 more results
-0.5 vs -0.5 Tadalafil score @ 24wk
NCT01178073 · Phase 3 · monotherapy
0.62 vs 0.08 placebo score @ 24wk
NCT02290613 · Phase 2 · registry result, not featured evidence
6MWD - Change 40.9 m @ 24wk10 mg
absolute change · m
No placebo or comparator arm
NCT00578786 · Phase 3 · registry result, not featured evidence
show 19 more results
37.2 m @ 48wk10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
28 m @ 96wk10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
27.8 m @ 144wk10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
32.5 m @ 24wk5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
27.9 m @ 48wk5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
23.2 m @ 96wk5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
18.8 m @ 144wk5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
38 m @ 24wk2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
24.9 m @ 48wk2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
6.7 m @ 96wk2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
0.7 m @ 144wk2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
53.59 m @ 12wk
NCT01808313 · Phase 3
64.36 m @ 24wk
NCT01808313 · Phase 3
34.8 m @ 24wk
NCT01338636 · Phase 4 · registry result, not featured evidence
395 m @ 36wk
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
368.71 m @ 12wk
NCT01330108 · Phase 4 · registry result, not featured evidence
23.4 m @ 12wk
NCT00423592 · Phase 2 · registry result, not featured evidence
42.2 m @ 12wk
NCT05437224 · Phase 3 · sponsor-reported, not registry data
53.4 m @ 24wk
NCT05437224 · Phase 3 · sponsor-reported, not registry data
Borg Dyspnea -0.51 score @ 48wk10 mg
absolute change · score
No placebo or comparator arm
NCT00578786 · Phase 3 · registry result, not featured evidence
show 12 more results
-0.65 score @ 96wk10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
-0.48 score @ 144wk10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
-0.59 score @ 48wk5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
-0.33 score @ 96wk5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
-0.14 score @ 144wk5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
-0.08 score @ 48wk2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
0.23 score @ 96wk2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
0.2 score @ 144wk2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
-0.34 score @ 12wk
NCT01808313 · Phase 3
-0.22 score @ 24wk
NCT01808313 · Phase 3
3 score @ 24wk
NCT01338636 · Phase 4 · registry result, not featured evidence
-0.5 score @ 12wk
NCT00423592 · Phase 2 · registry result, not featured evidence
NTproBNP 0.44 log @ 12wk
absolute change · log
No placebo or comparator arm
NCT01808313 · Phase 3
show 1 more result
0.37 log @ 24wk
NCT01808313 · Phase 3
Exercise Pulmonary Arterial Pressure -5.2 mmHg @ 24wk
absolute change · mmHg
No placebo or comparator arm
mPAP
NCT01338636 · Phase 4 · registry result, not featured evidence

+ 46 further endpoints in the CSV export.

Available safety results

Ambrisentan

Dropout rate
28.9%Ambrisentan Monotherapy
NCT01178073 · Phase 3 · monotherapy
show 15 more results
20.5%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · combination
7.5%
NCT01808313 · Phase 3
26.7%
NCT01338636 · Phase 4 · registry result, not featured evidence
4%
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
12.5%
NCT01330108 · Phase 4 · registry result, not featured evidence
24.2%
NCT00617305 · Phase 4 · registry result, not featured evidence
30.9%10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
34.7%5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
40.6%2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
10.5%
NCT02290613 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
6.3%5 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
15.8%2.5 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
6.3%1 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
19.4%
NCT00423592 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
17.8%Ambrisentan Monotherapy
NCT01178073 · Phase 3 · monotherapy
show 15 more results
11.3%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · combination
3.8%
NCT01808313 · Phase 3
—
NCT01338636 · Phase 4 · registry result, not featured evidence
—
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
—
NCT01330108 · Phase 4 · registry result, not featured evidence
12.1%
NCT00617305 · Phase 4 · registry result, not featured evidence
17.5%10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
19.5%5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
28.1%2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
—
NCT02290613 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
6.3%5 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
6.3%1 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
19.4%
NCT00423592 · Phase 2 · registry result, not featured evidence
Serious AEs
41.4%Ambrisentan Monotherapy
NCT01178073 · Phase 3 · monotherapy
show 15 more results
41.1%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · combination
8.2%
NCT01808313 · Phase 3
0%
NCT01338636 · Phase 4 · registry result, not featured evidence
12.5%
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01330108 · Phase 4 · registry result, not featured evidence
30.3%
NCT00617305 · Phase 4 · registry result, not featured evidence
53.1%10 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
52.1%5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
60.5%2.5 mg
NCT00578786 · Phase 3 · registry result, not featured evidence
5.3%
NCT02290613 · Phase 2 · registry result, not featured evidence
69.2%10 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
63.2%5 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
28.6%2.5 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00424021 · Phase 2 · registry result, not featured evidence
47.2%
NCT00423592 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
oedema peripheral 39.5%
headache 33.6%
diarrhoea 23%
NCT01178073 · Phase 3 · monotherapy
show 14 more results
oedema peripheral 44%
headache 41.1%
diarrhoea 20.9%
NCT01178073 · Phase 3 · combination
oedema peripheral 11.2%
flushing 8.2%
alanine aminotransferase increased 6.7%
NCT01808313 · Phase 3
worsening dyspnea on exertion 26.7%
nasal congestion 23.3%
peripheral edema 23.3%
NCT01338636 · Phase 4 · registry result, not featured evidence
edema 31.3%
lower extremity edema 6.3%
rash 3.1%
NCT01330108 · Phase 4 · registry result, not featured evidence
nasal congestion 30.3%
upper respiratory tract infection 24.2%
headache 21.2%
NCT00617305 · Phase 4 · registry result, not featured evidence
10 mg
oedema peripheal 52.1%
headache 31.4%
upper respiratory tract infection 25.8%
NCT00578786 · Phase 3 · registry result, not featured evidence
5 mg
oedema peripheal 36.3%
headache 23.3%
cough 17.8%
NCT00578786 · Phase 3 · registry result, not featured evidence
2.5 mg
oedema peripheal 30.2%
pulmonary hypertension 16.3%
anaemia 14%
NCT00578786 · Phase 3 · registry result, not featured evidence
edema 42.1% (placebo 21.1%)
headache 31.6% (placebo 31.6%)
diarrhea 21.1% (placebo 10.5%)
NCT02290613 · Phase 2 · registry result, not featured evidence
10 mg
oedema peripheral 57.7%
upper respiratory tract infection nos 53.8%
nausea 38.5%
NCT00424021 · Phase 2 · registry result, not featured evidence
5 mg
oedema peripheral 63.2%
cough 47.4%
dyspnoea exacerbated 47.4%
NCT00424021 · Phase 2 · registry result, not featured evidence
2.5 mg
bronchitis nos 57.1%
chest pain 57.1%
upper respiratory tract infection nos 57.1%
NCT00424021 · Phase 2 · registry result, not featured evidence
1 mg
alanine aminotransferase increased 100%
aspartate aminotransferase increased 100%
angina pectoris 50%
NCT00424021 · Phase 2 · registry result, not featured evidence
oedema peripheral 52.8%
headache 36.1%
dyspnoea exacerbated 33.3%
NCT00423592 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ambrisentan's landscape · F230's landscape